Peer Review History

Original SubmissionApril 2, 2023
Decision Letter - Nasser Hadal Alotaibi, Editor
Transfer Alert

This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.

PONE-D-23-08403Vital D: A Modifiable Occupational Risk Factor for Healthcare WorkersPLOS ONE

Dear Dr. Subramanian,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 27 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Nasser Hadal Alotaibi

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following in the Acknowledgments Section of your manuscript:

"The work was supported by funds from Mid and South Essex Hospitals charity. We also would like to thank research and development department Mid and South Essex hospitals U.K. for their support and junior doctors of Mid and South Essex hospitals who volunteered to assist in sample collection."

We note that you have provided additional information within the Acknowledgements Section that is not currently declared in your Funding Statement. Please note that funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

"- RS.

- No grant number

- The Mid and South Essex Hospitals Charity

-The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript"

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match.

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

4. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.  

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

5. Please amend your authorship list in your manuscript file to include author "A. Thangamuthu1‡, S. Muthumeenal2‡, K. Houston3‡, M. Everton1‡, S. Gowda 1‡, J.Zhang"

6. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Title: add UK Healthcare workers

Introduction, paragraph 1: Clarify winter months in the UK (i.e. Canada's winters last at least oct-march/april); expand on signs and symptoms of vit D def

Line 35 has an upside down exclamation mark.

Study population: Clarify the healthcare workers' positions i.e. nurses, docs, porters, respiratory therapists, etc

Line 108: missing period

All tables: I would place percentages behind the value i.e. 42 (6.6%)

Future considerations: Sample same group in winter months and then again at peak summer months

The article would be stronger if the authors expanded on the current literature, such as Sowah et al's 2017 article that was only briefly mentioned. Another suggstion: "Prevention of COVID-19 with oral vitamin D supplemental therapy in essential healthcare teams (PROTECT): protocol for a multicentre, triple-blind, randomised, placebo-controlled trial" by Ducharme et al (2023).

Reviewer #2: The authors aimed to investigate deficiency and insufficiency of serum Vitamin D levels in 639 volunteered front-line healthcare workers in the UK.

Introduction:

Other factors, such as hand hygiene, personal protective equipment (PPE) use, and vaccination status, also play crucial roles in infection prevention for front-line healthcare workers, which must be mentioned in the introduction or discussion section.

Materials and methods:

This study was carried out at Mid and South Essex NHS Foundation Trust, and the population does not represent UK front-line healthcare workers. Please modify it appropriately in different parts of the manuscript.

The first subsection of the Materials and methods is called study design. However, it is more about sample size calculation and justification.

Relevant dates, including periods of recruitment, exposure, and data collection, should be mentioned.

It is not well clear that the inclusion criteria were for workers at the “Mid and South Essex NHS Foundation Trust” or the National Health Service UK.

The size of participants from the sampling frame and the proportion who agreed to take part in this study are not mentioned.

Different subsections of materials and methods are mixed up together. Based on the STROBE statement, it could be good to have the following subsections: Study design, Setting, Participants, Variables, Measurements, Data sources, Bias, Study design, Quantitative variables, and Statistical methods.

Results:

Following the STROBE statement for writing and presenting the results could be more appropriate.

Adding the percentages to the counts in Table 1 makes it more informative, and it is possible to delete the two sentences in Lines 119-122.

It is similar to other tables, and combining Tables 1, 2, 3, 4 and 5 could be reasonable.

Marking the mean and median in Figure 1 could be informative.

Discussion:

The authors concluded that vitamin D deficiency/insufficiency puts the front-line UK NHS healthcare Workers at risk of infection with an unfavourable outcome beyond this study's design, measurements and analysis.

Reviewer #3: Well described manuscript with focus on the Health Care Workers (HCW). As vitamins are the vital one for the healthy living, much more studies are essential on this area of research in the upcoming years for the future benefits.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Specific responses that respond to each point raised by the academic editor and reviewer(s).

1. The manuscript has been confirmed to meet PLOS ONE's style requirements to the best of our knowledge.

2. Funding-related text has been removed from the manuscript. The funding statement does not need to be changed.

3. The grant information has been inserted within the funding information section to offer further clarification. No specific grant number exists and managed internally within the hospital trust.

4. The data remains available upon request due to potentially sensitive personal information.

a. Dr Rengarajan Subramanian remains the data custodian for this work and contactable via email (rengarajan.subramanian@nhs.net).

b. Data not uploaded for the above reasons.

5. Authorship list in manuscript in-keeping with request.

6. References: reference 23 has been included after review due to added content.

Reviewer #1 comments:

• Title: add UK Healthcare workers

- Change made

• Introduction, paragraph 1: Clarify winter months in the UK (i.e. Canada's winters last at least oct-march/april); expand on signs and symptoms of vit D def

- Clarified winter months and expanded on signs & symptoms

• Line 35 has an upside down exclamation mark.

- Removed

• Study population: Clarify the healthcare workers' positions i.e. nurses, docs, porters, respiratory therapists, etc

- We have expanded upon this in the manuscript

• Line 108: missing period

- Added

• All tables: I would place percentages behind the value i.e. 42 (6.6%)

- We have added these to tables were relevant

• Future considerations: Sample same group in winter months and then again at peak summer months

- No change made to manuscript

• The article would be stronger if the authors expanded on the current literature, such as Sowah et al's 2017 article that was only briefly mentioned. Another suggstion: "Prevention of COVID-19 with oral vitamin D supplemental therapy in essential healthcare teams (PROTECT): protocol for a multicentre, triple-blind, randomised, placebo-controlled trial" by Ducharme et al (2023).

- We have added to the manuscript based upon this and referenced under [23].

Reviewer #2 comments:

• Introduction: Other factors, such as hand hygiene, personal protective equipment (PPE) use, and vaccination status, also play crucial roles in infection prevention for front-line healthcare workers, which must be mentioned in the introduction or discussion section.

- Content added to manuscript

• Materials and methods: This study was carried out at Mid and South Essex NHS Foundation Trust, and the population does not represent UK front-line healthcare workers. Please modify it appropriately in different parts of the manuscript.

- Manuscript amended to account for this by referencing a sample of UK front-like healthcare workers.

• The first subsection of the Materials and methods is called study design. However, it is more about sample size calculation and justification.

- The materials and methods have been restructured based upon this feedback.

• Relevant dates, including periods of recruitment, exposure, and data collection, should be mentioned.

- Within manuscript

• It is not well clear that the inclusion criteria were for workers at the “Mid and South Essex NHS Foundation Trust” or the National Health Service UK.

- This has been clarified within manuscript.

• The size of participants from the sampling frame and the proportion who agreed to take part in this study are not mentioned.

- Participants section amended to clarify.

• Different subsections of materials and methods are mixed up together. Based on the STROBE statement, it could be good to have the following subsections: Study design, Setting, Participants, Variables, Measurements, Data sources, Bias, Study design, Quantitative variables, and Statistical methods.

- The materials and methods have been restructured based upon this feedback

• Results: Following the STROBE statement for writing and presenting the results could be more appropriate.

- Results section has been reorganised and amended to align with STROBE statement

• Adding the percentages to the counts in Table 1 makes it more informative, and it is possible to delete the two sentences in Lines 119-122.

- We have added these to tables were relevant

• It is similar to other tables, and combining Tables 1, 2, 3, 4 and 5 could be reasonable.

- This has not been changed as it was felt the combined tables was overwhelming when trialled.

• Marking the mean and median in Figure 1 could be informative.

- This has been added

• Discussion: The authors concluded that vitamin D deficiency/insufficiency puts the front-line UK NHS healthcare Workers at risk of infection with an unfavourable outcome beyond this study's design, measurements and analysis.

- Corrected within manuscript

Reviewer #3 comments:

• Can you specify the reason for Vitamin D deficiency particularly among the front line healthcare workers?

- This would be beyond the remit of this study to conclude this.

• Does any of the study population had COVID infection during the study period?

- Active COVID-19 was not tested for during the study. However, it can be assumed that anybody with active COVID-19 at the time of the study would have been self-isolating and therefore not in attendance or included upon study days.

• Does any of the study population was already on calcium supplementation?

- We established vitamin D supplementation during this study but did not collect data upon calcium supplementation.

• Does any of the study population had CKD or other chronic illness?

- A range of chronic illnesses were questioned upon within the study questionnaire including CKD, hypertension, diabetes, heart disease, chronic lung disease. A small number (n=3) reported a background of CKD.

Attachments
Attachment
Submitted filename: Response_to_Reviewers.docx
Decision Letter - Nasser Hadal Alotaibi, Editor

Vital D: A Modifiable Occupational Risk Factor of UK Healthcare Workers

PONE-D-23-08403R1

Dear Dr. Subramanian,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Nasser Hadal Alotaibi

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: Thanks for the ammendments.

The authors have adequately addressed your comments raised in a previous round of review and I feel that this manuscript is now acceptable for publication

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

**********

Formally Accepted
Acceptance Letter - Nasser Hadal Alotaibi, Editor

PONE-D-23-08403R1

PLOS ONE

Dear Dr. Subramanian,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Nasser Hadal Alotaibi

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .